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11 Abstract The visual analog scale (VAS) of pain is a
12 ubiquitous clinical and research tool with widespread
13 application in the rheumatic diseases. The objectives of
14 this study were to assess if patients report pain differently to
15 doctors or nurses, to determine reproducibility of this test
16 for diagnosis, age, gender, and treatment, and to ascertain
17 the level of pain in patients attending general rheumatology
18 clinics. Using a standardized line of exactly 100 mm and
19 instructions with identical wording, consecutive patients
20 attending general rheumatology clinics were asked to score
21 their perceived level of pain in the preceding week. Two
22 assessments were carried out, one before and one after the
23 clinic visit, and each patient was questioned by both a
24 doctor and a nurse. Differences between the first and
25 second VAS scores (VAS1 and VAS2) were recorded. One
26 hundred and eight patients completed the study (69 female).
27 VAS1 and VAS2 scores were administered by a similar
28 number of doctors and nurses. There was no significant
29 difference between mean VAS1 and VAS2 scores (41.1 vs.
30 41.4 mm, p=0.78). VAS1 and VAS2 differed by <4 mm in
31 59% of patients. Age, gender, or diagnosis did not influence
32 VAS1 or VAS2. Differences in scores were independent of
33 which health professional administered the scale (p=0.19).
34 Patients taking painkillers had higher mean VAS scores
35 (49 mm) compared with those not on analgesia (27 mm; p<
360.001). Anti-rheumatic treatment did not influence pain
37scores (p=0.13). The VAS is a reliable and effective
38method of pain assessment. Results are independent of
39which health professional administers the scale. Patients
40with rheumatic disease report their pain similarly regardless
41of diagnosis. However, pain control is sub-optimal in
42patients taking analgesia. Specific assessment of pain is,
43thus, important in patients attending rheumatology clinics.
44Keywords Analgesia . Pain . Rheumatic disease . VAS
45Introduction
46Pain is a significant and dominant symptom for many
47patients with rheumatic disease. However, the assessment
48of treatment effectiveness is frequently made by objective
49measures of inflammation or joint integrity rather than the
50patient’s perception of qualitative life improvement. Pain,
51as a subjective symptom, is when a patient is having
52difficulty to communicate to others and is affected by a
53variety of psychosocial and demographic factors1. Gender,
54ethnicity, cigarette smoking, and educational levels are
55thought to influence the reporting of pain by patients with
56rheumatoid arthritis (RA) [1]. Patients have been shown to
57complain different pain levels in separate outpatient clinics
58held on the same day [2]. Thus, several variables may
59influence the under-treatment or over-treatment of pain
60adversely affecting the patient in the process.
61It is not known if patients report pain differently to a
62variety of health professionals. If nurses have more
63dedicated time slots than physicians in a clinic setting, it
64is possible that patients will complain more to the former
65health professional. However, in our institution, doctors are
66the sole prescribers of analgesia, suggesting that patients
Clin Rheumatol
DOI 10.1007/s10067-008-0881-5
B. J. Sheane (*) : C. Doyle :C. O’Loughlin :D. Howard :
G. Cunnane
Department of Rheumatology, St James’s Hospital,
Dublin 8, Ireland
e-mail: sheaneb@yahoo.com
F. Doyle
Department of Psychology, Royal College of Surgeons in Ireland,
Dublin 2, Ireland
JrnlID 10067_ArtID 881_Proof# 1 - 01/04/2008
AUTHOR'S PROOF!
UN
CO
RR
EC
TE
D
PR
O
O
F
67 might be more likely to emphasize the severity of pain to
68 physicians rather than nurses.
69 The visual analog scale (VAS) is a validated tool for
70 measuring different variables, including pain [3–5]. When
71 compared with other scales, such as the numerical rating
72 scale and the verbal rating scale, it has been found that
73 results correlate closely [6–9].
74 The primary objective of this study was to ascertain
75 whether variability exists between individual patient pain
76 scores when the VAS is administered sequentially by
77 doctors and nurses. Secondly, we set out to establish the
78 reproducibility of the VAS for diagnosis, age, gender, and
79 treatment. Thirdly, we wanted to determine the level of pain
80 in patients attending general rheumatology clinics.
81 Materials and methods
82 Consecutive patients attending general rheumatology out-
83 patient clinics were asked to complete two horizontal visual
84 analog scales for pain. This consisted of marking a vertical
85 line across a horizontal line which measured exactly
86 100 mm. This mark was representative of their individual
87 pain levels for the previous 7 days. The VAS was
88 administered by both rheumatology nurses and doctors. If
89 a nurse-administered the first VAS (VAS1), a doctor would
90 administer the second VAS (VAS2), and vice versa. VAS1
91 was completed at the beginning of the clinic and VAS2
92 after the patient’s medical consultation.
93 Doctors and nurses delivered identically worded instruc-
94 tions to the patient for the completion of the VAS. These
95 were as follows: This is a line that represents your pain
96 level over the last 7 days. This end is “no pain” over the
97 last 7 days (point to “Zero”) and this end (point to “100”) is
98 the “worst possible pain”. I want you to draw a vertical line
99 over the point on the scale that you think best represents
100 your pain level over the last 7 days.
101 Patients were blinded from their first VAS score. Doctors
102 and nurses administering the VAS were prohibited from
103 demonstrating how to mark the scale, to prevent influenc-
104 ing patients’ scores.
105 Patients’ rheumatic diagnoses were recorded along with
106 age, gender, analgesia, and anti-rheumatic medication.
107 Patients who identified literacy difficulties were noted, but
108 direct questioning with regard to literacy was not pursued.
109 VAS scores were measured as the distance from “0” to
110 the vertical line placed by the patients along the scale. This
111 distance was measured in millimeters. Where a patient
112 placed an “X” over the VAS, rather than the vertical line as
113 instructed, the score was given as the point at which a
114 perpendicular line drawn from the crossover of the “X” fell
115 onto the scale. A note was made of the number of VAS
116completed incorrectly, i.e., placing a mark along the scale
117other than the vertical line requested in the instructions.
118Statistical analysis
119Student’s t-test was used to compare VAS scores for
120categorical variables, including gender, diagnosis, and the
121health professional administering the VAS. Pearson’s test
122was used to assess correlation for normally distributed data.
123A mixed-model analysis of variance (ANOVA) was used to
124examine for any effects of doctors or nurses on VAS scores
125and for the effect of time on the VAS. SPSS 14.0 for
126Windows was used to analyze the data.
127Results
128This was a cross-sectional study of patients with a variety
129of rheumatic diseases attending a general rheumatology
130clinic over a period of 4 weeks. All invited patients agreed
131to participate in the study (n=108). Demographic, diagnos-
132tic, and treatment data are outlined in Tables 1, 2, 3.
t1.1Table 1 Patient characteristics
Number (%) Mean SD t1.2
Patients 108 (100) t1.3
Age 55.5 14.7 t1.4
Female 69 (63.9) t1.5
DMARD* use 61 (56.5) t1.6
Analgesic use 68 (62.9) t1.7
t1.8DMARD Disease-modifying anti-rheumatic drug
t2.1Table 2 Diagnostic groupings
No. Percentage (%) t2.2
RA 38 35.2 t2.3
OA 15 13.9 t2.4
Spondyloarthritis 13 12.0 t2.5
Gout 3 2.8 t2.6
CTD 7 6.5 t2.7
Other 14 13.0 t2.8
Combination 18 16.7 t2.9
Total 108 100.0 t2.10
t2.11Spondyloarthritis included nine patients with psoriatic arthritis and
four with ankylosing spondylitis; CTD included three patients with
scleroderma, one SLE, one mixed connective tissue disease, one
Sjogren's syndrome and one Takayasu's arteritis; "Other" was
composed of fibromyalgia, polymyalgia rheumatica, regional pain
syndrome and lower back pain; "Combination" included those with
more than one rheumatic diagnosis
RA Rheumatoid arthritis, OA osteoarthritis, CTD connective tissue
disease
Clin Rheumatol
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133 All patients were fluent in English and demonstrated
134 good understanding of the instructions given. There was a
135 time difference of approximately 30 min between the
136 completion of VAS1 and VAS2 during which the patient
137 underwent a thorough clinical evaluation. The means of
138 VAS1 and VAS2 scores were 41.1 and 41.4 mms, respec-
139 tively (p=0.78; Table 4).
140 VAS1 and VAS2 scores correlated strongly (Pearson
141 correlation coefficient 0.898, p<0.001; Fig. 1). Most
142 patients complained of pain (mean VAS score=41.3 mm
143 ([VAS1 + VAS2]/2), range 0–100 mm). There was a
144 relatively even distribution of mean VAS scores among
145 the study population (Fig. 2).
146 VAS and health professionals
147 VAS1 and VAS2 were administered by an equivalent
148 number of nurses and doctors (Table 4). When a doctor
149administered VAS1, a nurse-administered VAS2 and vice
150versa. No significant difference was observed between VAS
151scores administered by doctors or nurses. The mean of all
152VAS scores administered by doctors was 40.1 mm while the
153mean for VAS scores administered by nurses was 42.1 mm
154(p=0.67). The mean score for doctor-administered VAS1
155was 38.1 mm in comparison with 44.1 mm for nurse-
156administered VAS1 (p=0.26). The mean of VAS2 admin-
157istered by doctors was 42.9 mm and 39.9 mm by nurses
158(p=0.58).
159VAS and rheumatic diagnosis
160VAS scores did not differ significantly between rheumatic
161diagnoses. The largest diagnostic cohort comprised RA (n=
16238), while 13.9% had osteoarthritis and 12% seronegative
163spondyloarthritis. A variety of other rheumatic diseases
164were also represented and are detailed in Table 2. There
165was no significant difference in VAS scores between
166‘inflammatory’ (RA, spondyloarthropathy) and ‘non-
167inflammatory’ diseases (p=0.76).
168VAS and medication use
169Table 3 outlines the number of patients prescribed a variety
170of analgesics. Forty patients were not using any painkillers
171or anti-inflammatory drugs, while 68 were taking daily
172analgesics, either single agents or a combination of
173products. VAS scores were significantly higher in those
174patients taking analgesics (mean VAS score 49.5 mm) in
175comparison with patients using none (mean VAS score
17627.4 mm; p<0.001; Fig. 3). Patients taking a combination
177of analgesics had higher VAS scores (mean VAS 58.5 mm)
178compared with those using single analgesic agents (mean
t3.1 Table 3 Types and frequencies of analgesic medication
Analgesic No. Percentage (%)t3.2
Paracetamol 15 13.9t3.3
NSAID 12 11.1t3.4
Topical NSAID 1 .9t3.5
Paracetamol/codeine (500 mg/8 mg) 14 13.0t3.6
Paracetamol/codeine (500 mg/30 mg) 5 4.6t3.7
Tramadol 1 .9t3.8
Any combination 18 16.7t3.9
Other (nerve block, strong opiate) 2 1.9t3.10
No analgesia 40 37.0t3.11
Total 108 100.0t3.12
t3.13 NSAID Non-steroidal anti-inflammatory drug
t4.1 Table 4 Mean and median values of the VAS scores
No. (%) Mean (mm) Median (mm) SD (mm) P valuet4.2
VAS1 108 (100) 41.1 41.0 27.4 0.78t4.3
VAS2 108 (100) 41.4 38.5 27.0t4.4
VAS1 by doctors 53 (49.1) 38.1 37.0 26.9 0.26t4.5
VAS1 by nurses 55 (50.9) 44.1 46.0 27.7t4.6
VAS2 by doctors 55 (50.9) 42.9 39.0 27.1 0.58t4.7
VAS2 by nurses 53 (49.1) 39.9 36.0 27.2t4.8
VAS1 + VAS2at4.9
Doctors 108 (100) 40.1 38.5 26.9 0.67t4.10
Nurses 108 (100) 42.1 39.0 27.4t4.11
VAS2-VAS1bt4.12
Doctorsc 53 (49.1) 1.92 0.0 8.9 0.19t4.13
Nursesc 55 (50.9) −1.22 1.0 14.7t4.14
t4.15 a VAS1 + VAS2 represents the mean of all VAS scores administered by doctors and by nurses
b VAS2 − VAS1 refers to the difference between VAS1 and VAS2
c Health professional administering VAS1
Clin Rheumatol
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F179 VAS 46 mm). However, this difference did not reach
180 statistical significance (p=0.1).
181 Sixty-one patients were taking disease-modifying anti-
182 rheumatic drugs (DMARD), either as single agents (n=20)
183 or in combination (n=41). Mean VAS scores were 35.8 mm
184 for those prescribed one DMARD and 45.9 mm for those
185 on combination treatment. However, no significant differ-
186 ence was observed (p=0.13).
187 VAS and age and gender
188 Age had no influence on VAS1 or VAS2 scores (p=0.51
189 and 0.89, respectively). There was no correlation between
190 age and the difference between VAS1 and VAS2 (p=0.18).
191 The mean VAS1 score for males was 37.2 and 43.4 mm
192 for females (p=0.26) while mean VAS2 scores were 38.5
193 and 43.1 mm for males and females, respectively (p=0.40).
194 These VAS scores were not influenced by which health
195 professional administered the test (p>0.5). Differences in
196 VAS scores, [VAS2−VAS1], between males and females
197 were not significant (p=0.51).
198VAS and Literacy
199Two patients identified themselves as having poor literacy
200skills. The first patient had a 20+ mm discrepancy between
201VAS1 and VAS2. The second patient marked the scale
202incorrectly, but both VAS1 and VAS2 correlated.
203Sixteen patients (14.8%) marked the VAS incorrectly by
204placing an “X” on the scale or a mark that did not conform
205to the vertical line requested in the instructions. While those
206who marked the VAS incorrectly had a tendency to rate
207their pain at the 50% range (mean VAS1 and VAS2 of 51.1
208and 52.3 mm, respectively), compared to those correctly
209marking the VAS (39.4 and 39.6 mm), this was not
210significant (p=0.11 for VAS1; p=0.08 for VAS2).
211There was no significant difference between the means
212of [VAS2−VAS1] for those marking the VAS correctly and
213incorrectly (p=0.76).
214Discussion
215This study assessed the reliability of the visual analog scale
216of pain in patients attending general rheumatology clinics.
217The results were not influenced by which health profes-
218sional administered the test and scores were similar
219regardless of age, gender, and rheumatic diagnosis.
220Most patients in this study reported joint pain. However,
221levels of pain did not differ significantly between rheumatic
222diagnoses or with DMARD use. Where joint integrity is
223preserved, but inflammation is present, the dominant
224symptom may be ‘stiffness’ rather than severe pain. Thus,
225a VAS of joint stiffness may be a better symptom
226discriminator between rheumatic diseases.
227Patients taking analgesia reported higher pain levels than
228those who were not using painkillers or non-steroidal anti-
Fig. 3 This bar graph highlights the difference in mean VAS scores
between those taking and not taking analgesia (p<0.001)
Fig. 2 The distribution of mean VAS scores ([VAS1 + VAS2]/2) and
the proportion of patients within each of the VAS ranges
Fig. 1 The plot is linear signifying correlation between VAS1 and
VAS2 scores
Clin Rheumatol
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229 inflammatory drugs. This suggests that pain control in those
230 prescribed analgesia in the outpatient setting is inadequate.
231 As there are several modes of action for different
232 analgesics, closer attention should be paid to the efficacy
233 of pain management in rheumatology clinics.
234 Literacy may influence the ability to complete a VAS
235 [10]. Although such skills were not formally tested in this
236 study, 15% of patients did not complete the test according
237 to the carefully worded instructions, suggesting that this
238 issue should be taken into account when using this type of
239 measurement.
240 Completing two VAS tests within a short time frame
241 may suggest that the second result could be influenced by
242 the first, in what has been called the halo effect [7].
243 However, all of the patients in this study underwent a
244 thorough clinical assessment between VAS1 and VAS2,
245 thus, reducing the likelihood of this phenomenon.
246 This study demonstrates that the VAS is an accurate
247 measure of pain in patients with rheumatic disease and is
248 reproducible regardless of whether it is administered by a
249 doctor or nurse. It is not influenced by age, gender,
250 diagnosis, or DMARD treatment. However, literacy and
251 educational level may affect the ability to understand and
252 complete the VAS instructions and should be taken into
253 account in future studies using this assessment tool. Higher
254 pain scores were reported in patients taking analgesics
255 suggesting that pain control may be sub-optimal. Tradi-
256 tional outcomes in the treatment of rheumatic disease
257 include the reduction of inflammation and joint destruction.
258However, the VAS has an important role in ensuring that
259pain levels are also optimally suppressed.
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